Advertisement
Screener

AYTU BIOPHARMA, INC (AYTU) Increase (Decrease) in Other Current Assets

2.8 / 5 stars · 68/120 Roast Me

AYTU BIOPHARMA, INC Increase (Decrease) in Other Current Assets

AYTU BIOPHARMA, INC (AYTU) reported Increase (Decrease) in Other Current Assets of -$6.07 million for the 9-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2021-05-17

  • AYTU BIOPHARMA, INC increase (decrease) in other current assets for the quarter ending 2021-03-31 was -$3.77M, a 1803.78% decline year-over-year.
  • AYTU BIOPHARMA, INC increase (decrease) in other current assets for the quarter ending 2020-12-31 was -$2.53M, a 1952.88% decline year-over-year.
  • AYTU BIOPHARMA, INC increase (decrease) in other current assets for the quarter ending 2020-09-30 was $237.72K.
  • AYTU BIOPHARMA, INC increase (decrease) in other current assets for the quarter ending 2020-06-30 was $3.39M.
  • AYTU BIOPHARMA, INC increase (decrease) in other current assets for fiscal 2020 was $3.75M.
  • AYTU BIOPHARMA, INC increase (decrease) in other current assets for fiscal 2019 was $0.00.
Period endIncrease (Decrease) in Other Current Assets 3 monthIncrease (Decrease) in Other Current Assets 6 monthIncrease (Decrease) in Other Current Assets 9 monthIncrease (Decrease) in Other Current Assets 12 month
2021-03-31-$3.77M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-17
-$6.30M
derived: sum of 2 quarters · filed 2021-05-17
-$6.07M
10-Q · filed 2021-05-17
-$2.67M
derived: sum of 4 quarters · filed 2021-05-17
2020-12-31-$2.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11
-$2.30M
10-Q · filed 2021-02-11
$1.10M
derived: sum of 3 quarters · filed 2021-02-11
$1.32M
derived: sum of 4 quarters · filed 2021-05-17
2020-09-30$237.72K
10-Q · filed 2020-11-12
$3.63M
derived: sum of 2 quarters · filed 2020-11-12
$3.85M
derived: sum of 3 quarters · filed 2021-05-17
$3.99M
derived: sum of 4 quarters · filed 2021-05-17
2020-06-30$3.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06
$3.61M
derived: sum of 2 quarters · filed 2021-05-17
$3.75M
derived: sum of 3 quarters · filed 2021-05-17
$3.75M
10-K · filed 2020-10-06
2020-03-31$221.33K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-17
$358.02K
derived: sum of 2 quarters · filed 2021-05-17
$358.02K
10-Q · filed 2021-05-17
$358.02K
derived: sum of 4 quarters · filed 2021-05-17
2019-12-31$136.69K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11
$136.69K
10-Q · filed 2021-02-11
$136.69K
derived: sum of 3 quarters · filed 2021-02-11
$136.69K
derived: sum of 4 quarters · filed 2021-02-11
2019-09-30$0.00
10-Q · filed 2020-11-12
$0.00
derived: sum of 2 quarters · filed 2020-11-12
$0.00
derived: sum of 3 quarters · filed 2020-11-12
2019-06-30$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06
$0.00
derived: sum of 2 quarters · filed 2020-10-06
$0.00
10-K · filed 2020-10-06
2019-03-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-15
$0.00
10-Q · filed 2020-05-15
2018-12-31$0.00
10-Q · filed 2020-02-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
NextCure, Inc. (NXTC)United States$0.024B-0.15
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87
ARTELO BIOSCIENCES, INC. (ARTL)United States$0.023B
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
Cocrystal Pharma, Inc. (COCP)United States$0.022B
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77